Creative Planning
REGN icon

Creative Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

Creative Planning’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-400
Closed -$8K – 4794
2016
Q3 		$8K Buy
400
+300
+300% +$120K ﹤0.01% 3661
2016
Q2 		$3K Sell
100
-100
-50% -$38.5K ﹤0.01% 3908
2016
Q1 		$4K Buy
+200
New +$82.4K ﹤0.01% 3713

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Creative Planning's REGN Position: Q1 2026 in Review

Creative Planning increased its Regeneron Pharmaceuticals (REGN) stake by 33% in Q1 2026, buying an estimated $7.67M and bringing the position to 40,152 shares worth $31M. The position accounts for 0.02% of the portfolio, ranked #305.

Creative Planning first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Creative Planning held 40,152 shares of Regeneron Pharmaceuticals worth $31M as of Q1 2026.
  • Creative Planning bought 10,018 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.67M.
  • Regeneron Pharmaceuticals made up 0.02% of Creative Planning's portfolio in Q1 2026, its #305 holding.
  • Creative Planning first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.